Corrigendum: CREB5 hypermethylation involved in the ganglioside GM1 therapy of Parkinson's disease
Rui Wang1† Shanshan Tong1† Mengdi Wang1 Junjie Zou2 Nan Wang3 Fengjiao Sun3 Xiaosheng Zhou1* Jinbo Chen1 
Hongcai Wang1*- 1Department of Neurology, Binzhou Medical University Hospital, Binzhou, Shandong, China
- 2Department of Neurology, Penglai People's Hospital, Yantai, China
- 3Medical Research Center, Binzhou Medical University Hospital, Binzhou, Shandong, China
A corrigendum on
CREB5 hypermethylation involved in the ganglioside GM1 therapy of Parkinson's disease
by Wang, R., Tong, S., Wang, M., Zou, J., Wang, N., Sun, F., Zhou, X., Chen, J., and Wang, H. (2023). Front. Aging Neurosci. 15:1122647. doi: 10.3389/fnagi.2023.1122647
In the published article, there was an error in Figure 5A, Image d as published. We inadvertently used the wrong figure and need to correct the Figure 5A, Image d. The other elements of the Figure 5 remain the same. The corrected Figure 5A, Image d and its caption appear below.
Figure 5. GM1 prevented ROT-induced cell apoptosis. (A, B) Impaired neurite outgrowth was inhibited by GM1 addition. Scale bar = 10 μm. (C, D) GM1 decreased ROT-induced cell apoptosis. *P < 0.05; ****P < 0.0001; #,##P > 0.05.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: monosialotetrahexosylganglioside (GM1), Parkinson's disease (PD), DNA methylation, rotenone (ROT), cell apoptosis
Citation: Wang R, Tong S, Wang M, Zou J, Wang N, Sun F, Zhou X, Chen J and Wang H (2023) Corrigendum: CREB5 hypermethylation involved in the ganglioside GM1 therapy of Parkinson's disease. Front. Aging Neurosci. 15:1250440. doi: 10.3389/fnagi.2023.1250440
Received: 30 June 2023; Accepted: 24 July 2023;
Published: 02 August 2023.
Edited and reviewed by: Jorge Busciglio, University of California, Irvine, United States
Copyright © 2023 Wang, Tong, Wang, Zou, Wang, Sun, Zhou, Chen and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Hongcai Wang, whc2891@126.com; Xiaosheng Zhou, zhouxiaosheng001@126.com
†These authors have contributed equally to this work and share first authorship